
    
      This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group
      study to evaluate the clinical and biologic efficacy, as well as the safety of SC doses of
      AMG 557/MEDI5872 in adult subjects with Primary Sj√∂gren's Syndrome.
    
  